Skip to main content

Approval expected for GW Pharmaceuticals' product

The Food and Drug Administration is expected to approve GW Pharmaceuticals' (Nasdaq: GWPH) seizure treatment that is made with cannabidiol. The stock price leaped $13.55 to close at $134.13.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.